Filing Flows › Ultragenyx Pharmaceutical (RARE) › Royalty revenue
Ultragenyx Pharmaceutical (RARE) Royalty revenue by quarter
Ultragenyx Pharmaceutical's Royalty revenue was $68.0M in Q3 2026 (third quarter 2026), -33% from Q2 2026. Over the last 7 quarters it ranged from $47.0M (Q1 2026) to $106M (Q4 2025).
| Quarter | Royalty revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $68.0M | -33% | +5% |
| Q2 2026 | $102M | +117% | +19% |
| Q1 2026 | $47.0M | -55% | -2% |
| Q4 2025 | $106M | +63% | — |
| Q3 2025 | $64.9M | -24% | — |
| Q2 2025 | $85.7M | +79% | — |
| Q1 2025 | $47.8M | — | — |
Q3 2026 at a glance
Ultragenyx Pharmaceutical, Q3 2026: revenue $173M (+8% year over year), operating margin -63.6%, net loss $118M, operating cash flow −$43.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Ultragenyx Pharmaceutical's Royalty revenue?
Ultragenyx Pharmaceutical's Royalty revenue was $68.0M in Q3 2026 (third quarter 2026), -33% from Q2 2026.
How has Ultragenyx Pharmaceutical's Royalty revenue changed?
Over the last 7 quarters it ranged from $47.0M (Q1 2026) to $106M (Q4 2025).
Q3 2026 results → · How Ultragenyx Pharmaceutical makes money →